Treatment of digital ulcers in systemic sclerosis

Nature Reviews Rheumatology

Volumn 7, Issue 1, 2011, Pages 5-6

  Lambova, Sevdalina ^a   Müller Ladner, Ulf ^b  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTANOID; SILDENAFIL; SITAXSENTAN; VASODILATOR AGENT; AMINOTRANSFERASE; SULFONAMIDE;

CLINICAL PRACTICE; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EARLY INTERVENTION; ENDOTHELIUM INJURY; FINGER; FOLLOW UP; HAND DISEASE; HEART VENTRICLE TACHYCARDIA; HUMAN; IMMUNOPATHOGENESIS; PERIPHERAL EDEMA; PHYSICAL DISABILITY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RAYNAUD PHENOMENON; REVIEW; SECONDARY INFECTION; SIDE EFFECT; SKIN BLOOD VESSEL DISORDER; SKIN ULCER; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; WOUND HEALING; BLOOD; DRUG ANTAGONISM; HAND; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIARRHEA; FINGERS; HAND; HUMANS; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; TRANSAMINASES; TREATMENT OUTCOME;

EID: 78650965944     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.207     Document Type: Review

References (10)

1. Hachulla, e. et al. natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J. Rheumatol. 34 2423-2430 (2007)
2. walker, U. A. et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the eULAR scleroderma Trials and Research group database. Ann. Rheum. Dis. 66, 754-763 (2007).
3. Galluccio, F. & Matucci-Cerinic, M. Registry evaluation of digital ulcers in systemic sclerosis. Int. J. Rheumatol. doi:10.1155/ 2010/363679.
4. Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPiDs-2 randomized, doubleblind, placebo-controlled trial. Ann. Rheum. Dis. doi:10.1136/ard.2010.130658.
5. Abraham, D. & Dashwood, M. endothelin-role in vascular disease. Rheumatology (Oxford) 47 (suppl. 5), v23-v24 (2008).
6. Rademaker, M. et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynauds phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298, 561-564 (1989).
7. scorza, R. et al. effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynauds phenomenon. A randomized, controlled study. Clin. Exp. Rheumatol. 19, 503-508 (2001).
8. Kowal-Bielecka, O. et al. eULAR recommendations for the treatment of systemic sclerosis: a report from the eULAR scleroderma Trials and Research group (eUsTAR). Ann. Rheum. Dis. 68, 620-628 (2009).
9. Humbert, M. & Cabane, J. successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelia receptor antagonist bosentan. Rheumatology (Oxford) 42, 191-193 (2003).
10. Korn, J. H. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelia receptor antagonist. Arthritis Rheum. 50, 3985-3993 (2004).